TNF and myeloid sarcoma: Patients with inflammatory bowel diseases (IBD) treated with anti-tumor necrosis factor (TNF) and patients with multiple sclerosis (MS) or rheumatic disease receiving treatment with anti-CD20 therapies showed impaired humoral immune responses directly after infection [4–7].